Document:

Exhibit 4.9

 

CONFIDENTIAL
TREATMENT REQUESTED

 

[***] –
CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN

REDACTED ARE
MARKED WITH BRACKETS (“[***]”). THE OMITTED MATERIAL HAS

BEEN FILED SEPARATELY
WITH THE UNITED STATES SECURITIES AND EXCHANGE

COMMISSION.

 

SECURITY AGREEMENT

 

This Security Agreement
(this “Agreement”), dated as of February 4, 2013, is entered into between Eclat Pharmaceuticals LLC
(“Eclat”) in favor of the parties and in the capacities identified on the signature page of this Agreement as
a secured party (together, the “Secured Party”).

 

WITNESSETH:

 

WHEREAS, Eclat
has entered into a Royalty Agreement, dated as of December 31, 2012, with the Buyers named therein (the “Royalty Agreement”),

 

WHEREAS,
Flamel Holdings Inc., the holder of the equity interests in Eclat, has entered into a Facility Agreement dated as of December
31, 2012 with the Lenders named therein (the “Facility Agreement”), and

 

WHEREAS, certain
capitalized terms used in this Agreement are defined in Section 9,

 

NOW, THEREFORE,
in consideration of the mutual agreements set forth herein, Eclat and the Secured Party agree as follows:

 

1.          Grant
of Security Interest.

 

(a)          To
secure payment and performance of the Obligations, Eclat hereby grants to Secured Party a security interest (the “Security
Interest”) in the Product Intellectual Property and Product Regulatory Rights and all proceeds and products thereof (the
“Collateral”).

 

Notwithstanding anything
to the contrary contained herein, the Security Interest shall not extend to, and the Collateral shall not include (collectively,
the “Excluded Collateral”): (1) any contract of Eclat if the grant of the Security Interest in such contract,
under the terms of or under applicable laws, would result in the termination thereof or give the other parties thereto the right
to terminate, accelerate or otherwise alter Eclat’s rights, titles and interests thereunder (including upon the giving of
notice or the lapse of time or both); provided, however, that (i) any limitation described above shall only apply to the extent
that such limitation could not be rendered ineffective pursuant to the UCC or any other applicable laws and (ii) if such limitations
is eliminated to the extent sufficient to permit any such item to become Collateral hereunder, the Security Interest in such contract
shall be automatically and simultaneously granted hereunder and such contract shall be included as Collateral hereunder.

 

    	 

    	 

    

  

(b)          Eclat
shall not to enter into any agreement that prohibits the creation of the Security Interest other than (i) customary restrictions
and conditions contained in agreements relating to the sale of property pending such sale, (ii) customary provisions in contracts
restricting the assignment thereof, and (iii) restrictions on the pledge of interests in any joint venture contained in the applicable
joint venture agreement.

 

(c)          Perfection
of Security Interests.

 

(i)          Eclat
authorizes Secured Party to file such financing statements naming Secured Party or its designee as the secured party and Eclat
as debtor, as Secured Party may require in order to perfect the Security Interest required by Article 9 of the UCC, together with
any amendment and continuations with respect thereto; provided, however, that if requested by Eclat, any such financing statement
or amendment or continuation shall specifically identify any Excluded Collateral. Eclat shall not file, or permit or cause to be
filed, any correction or termination statement with respect to any financing statement (or amendment or continuation thereof).

 

(ii)         Eclat
shall take any other action reasonably requested by Secured Party to cause the attachment and perfection of, and the ability of
Secured Party to enforce, the Security Interest.

 

2.          Notice
of Change in Certain Information. Eclat shall not change (a) its name as it appears in official filings in the state of its
organization, (b) its chief executive office or sole place of business, (c) the type of entity that it is, (d) its organization
identification number, if any, issued by its state of organization, or (e) its state of organization, in each case, unless all
filings have been made under the UCC that are required in order for the Secured Party to continue following such change to have
a valid and perfected security interest in the Collateral.

 

3.          Remedies.

 

Upon the occurrence
and during the continuance of an Event of Default, (i) Secured Party shall have the right to exercise any right and remedy provided
for herein, under the UCC and at law or equity generally, including, without limitation, the right to foreclose the Security Interest
and to realize upon any Collateral by any available judicial procedure and/or to take possession of the Collateral with or without
judicial process; and (ii) with or without having the Collateral at the time or place of sale, Secured Party may sell the Collateral,
or any part thereof, at public or private sale, at any time or place, in one or more sales, at such price or prices, and upon such
terms, either for cash, credit or future delivery, as Secured Party may elect.

 

4.          Representations
and Warranties. Eclat hereby represents and warrants to Secured Party as of the date
hereof that:

 

(a)          Eclat
is a limited liability company duly organized and validly existing under the laws of Delaware.

 

(b)          The
exact legal name of Eclat is set forth on the signature page of this Agreement.

 

    	2

    	 

    

  

(c)          The
chief executive office and mailing address of Eclat are located only at the address set forth on Schedule 4(c).

 

5.          Expenses;
Secured Party’s Right to Perform on Eclat’s Behalf. 

 

(a)          Eclat’s
agreements hereunder shall be performed by it at its sole expense.

 

(b)          If
Eclat shall fail to do any act which it has agreed to do hereunder, Secured Party may (but shall not be obligated to) do or cause
the act to be done, either in its name or on behalf of Eclat, and Eclat hereby irrevocably authorizes Secured Party so to act.

 

6.          No
Waivers of Rights hereunder; Rights Cumulative.

 

(a)          No
delay by Secured Party in exercising any right hereunder, or in enforcing any of the Obligations, shall operate as a waiver thereof,
nor shall any single or partial exercise of any right preclude other or further exercises thereof or the exercise of any other
right. No waiver of any of the Obligations shall be enforceable against Secured Party unless in writing and signed by Secured Party,
and unless it expressly refers to the provision affected, any such waiver shall be limited solely to the specific event waived.

 

(b)          All
rights granted Secured Party hereunder shall be cumulative and shall be supplementary of and in addition to those granted or available
to Secured Party under any other agreement with respect to the Obligations or under applicable law and nothing herein shall be
construed as limiting any such other right.

 

7.          Termination.
This Agreement shall continue in full force and effect until all Obligations shall have been
paid in full.

 

8.          Applicable
Law and Consent to Non-Exclusive New York Jurisdiction.

 

(a)          This
Agreement shall be construed in accordance with the laws of the State of New York, without giving effect to the conflicts of laws
principles thereof other than Sections 5-1401 and 5-1402 of the General Obligations Law of such State.

 

(b)          Each
of Eclat and Secured Party (together, the “Parties” and individually, a “Party”) irrevocably
submits to the jurisdiction of the state and federal courts sitting in The City of New York, borough of Manhattan, for the adjudication
of any dispute hereunder or in connection herewith, and hereby waives, and agrees not to assert in any suit, action or other proceeding,
any claim that it is not personally subject to the jurisdiction of any such court or that such court, action or other proceeding
is improper or is an inconvenient venue for such proceeding. Final non-appealable judgment against any Party in any such action,
suit or other proceeding shall be conclusive and may be enforced in any jurisdiction by suit on the judgment. Nothing contained
in this Agreement shall affect the right of any Party to commence legal proceedings in any court having jurisdiction, or concurrently
in more than one jurisdiction, or to serve process, pleadings and other legal papers upon another Party in any manner authorized
by the laws of any such jurisdiction. Each Party irrevocably waives, to the fullest extent permitted by applicable law, any objection
which it may have to the laying of venue of any action, suit or other proceeding arising out of this Agreement, brought in the
courts of the State of New York or in the United States District Court for the Southern District of New York, and any claim that
any such action, suit or other proceeding brought in any such court has been brought in an inconvenient forum.

 

    	3

    	 

    

  

(c)          Each
Party waives any right to demand a trial by jury in any action, suit or other proceeding arising out of this Agreement.

 

(d)          To
the extent that the Parties may, in any suit, action or other proceeding brought in any court arising out of or in connection with
this Agreement, be entitled to the benefit of any provision of law requiring any Party in such suit, action or other proceeding
to post security for the costs of any other Party, or to post a bond or to take similar action, the Parties hereby waive such benefit,
in each case to the fullest extent now or hereafter permitted under any applicable laws.

 

9.          Additional
Definitions. All references to the plural herein shall also mean the singular and to the
singular shall also mean the plural unless the context otherwise requires. All references to Eclat and Secured Party shall include
their respective successors and assigns. The words “hereof”, “herein”, “hereunder”, “this
Agreement” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not any particular
provision of this Agreement and as this Agreement now exists or may hereafter be amended, modified, supplemented, extended, renewed,
restated or replaced. The word “including” when used in this Agreement shall mean “including, without limitation”.
The words “it” or “its” as used herein shall be deemed to refer to individuals and to business entities.

 

“Copyright”
means (i) all copyrights and moral rights, including the legal right provided by the Copyright Act of 1976, as amended, to the
expression contained in any work of authorship fixed in any tangible medium of expression together with any similar rights arising
in any other country as a result of statute or treaty, and all registrations, applications, renewals, extensions and reversions
thereof.

 

“Event of
Default” means (i) the incurrence and continuance of an Event of Default (as defined in the Facility Agreement and (ii)
the failure by Eclat to comply with the Royalty Agreement.

 

“Intellectual
Property” means any intellectual property, in any medium, of any kind or nature whatsoever, now or hereafter owned or
acquired or received by Eclat or in which Eclat now holds or hereafter acquires or receives any right, interest or license, and
shall include, in any event, any copyright rights, copyright applications, copyright registrations and like protections in each
work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections,
including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks,
service marks and any applications therefor, whether registered or not, and the goodwill of the business of Eclat connected with
and symbolized thereby, know-how, operating manuals, inventions, formulae, processes, gene sequences, cell lines, assays, biological
materials, compounds, compound libraries, research, clinical and commercial compounds, along with the associated active pharmaceutical
ingredients and related formulations (other than Inventory), new drug applications and investigational new drug applications or
other regulatory filings relating to any drugs or compounds, trade secret rights, rights to unpatented inventions, and any claims
for damage by way of any past, present, or future infringement of any of the foregoing, and any licenses to use any of the foregoing.

 

    	4

    	 

    

  

“Mark”
means any word, name, symbol, logos or device used by a Person to identify its goods or services, whether or not registered, all
goodwill associated therewith, and any right that may exist to obtain a registration with respect thereto from any governmental
body and any rights arising under any such application, together with all registrations, renewals, extensions and reversions thereof.
As used in this Agreement, the term “Mark” includes all of the foregoing, including trademarks and service marks.

 

“Obligations”
means:

 

(1)         the
full and prompt payment by Eclat when due of all obligations and liabilities to Secured Party under the Royalty Agreement;

 

(2)         the
full and prompt payment by Flamel US Holdings, Inc. when due of all obligations and liabilities to Secured Party under the Facility
Agreement;

 

(3)         any
and all sums advanced by Secured Party to preserve the Collateral or to preserve the Security Interest; and

 

(4)         in
the event of any proceeding for the collection or enforcement of any obligations or liabilities of Eclat referred to in the immediately
preceding clauses (1), (2) and (3), the reasonable and documented out-of-pocket expenses of re-taking, holding, preparing for sale,
selling or otherwise disposing of or realizing on the Collateral, or of any other exercise by Secured Party of its rights hereunder,
together with reasonable and documented out-of-pocket attorneys’ fees and court costs.

 

“Patent”
means any patent granted by the United States Patent and Trademark Office or by the comparable agency of any other country, and
any renewal, thereof, and any rights arising under any patent application filed with the United States Patent and Trademark Office
or the comparable agency of any other country and any rights that may exist to file any such application, including all continuations,
divisional, continuations-in-part and provisionals and patents issuing thereon, and all reissues, reexaminations, substitutions,
renewals and extensions thereof.

 

“Person”
or “person” shall mean any individual, sole proprietorship, partnership, corporation, limited liability company,
limited liability partnership, business trust, unincorporated association, joint stock corporation, trust, joint venture or other
entity or any government or any agency or instrumentality or political subdivision thereof.

 

“Product Intellectual
Property” shall mean all Proprietary Rights held or licensed by Eclat and their Affiliates that is, or may hereafter
be, necessary to develop, make, have made, promote, market or sell the Products in the United States.

 

“Product Regulatory
Rights” shall mean each and every investigational new drug application or new drug application and/or state license or
registration that is held or obtained (if any) that is necessary
to develop, conduct clinical trials relating to, manufacture, have manufactured, distribute, promote, market or sell the Products
in the United States.

 

    	5

    	 

    

  

[***] –
CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN

REDACTED ARE
MARKED WITH BRACKETS (“[***]”). THE OMITTED MATERIAL HAS

BEEN FILED SEPARATELY
WITH THE UNITED STATES SECURITIES AND EXCHANGE

COMMISSION.

 

“Products”
shall mean (i) the drugs [***], [***], [***] and [***], and (ii) [***].

 

“Proprietary
Rights” means, with respect to a Person, all Copyrights, Marks, Trade Names, Trade Secrets, Patents, and Intellectual
Property owned or used by such Person.

 

“Trade Names” means any
words, name or symbol used by a Person to identify its business.

 

“Trade Secrets” means
business or technical information of any Person including, but not limited to, customer lists, marketing data and know-how, that
is not generally known to other Persons who are not subject to an obligation of nondisclosure and that derives actual or potential
commercial value from not being generally known to other Persons.

 

“UCC”
shall mean the Uniform Commercial Code as in effect in the State of New York and any successor statute, as in effect from time
to time (except that terms used herein which are defined in the Uniform Commercial Code as in effect in the State of New York on
the date hereof shall continue to have the same meaning notwithstanding any replacement or amendment of such statute); provided,
however, that if, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of the Security
Interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New
York, the term “UCC” shall mean the Uniform Commercial Code as in effect at such time in such other jurisdiction for
purposes of the provisions hereof relating to such attachment, perfection or priority and for purposes of definitions related to
such provisions.

 

10.         Notices.
    Any notice, request or other communication to be given under this Agreement shall be in
writing. Such communication shall be deemed to have been duly given or made when it shall be delivered by hand, courier (confirmed
by facsimile), or facsimile or electronic mail (with a hard copy delivered within two (2) Business Days) to the Party to which
it is required or permitted to be given at such Party’s address specified below or at such other address as such Party shall
have designated by notice to the other Parties.

 

For Eclat:

 

Eclat Pharmaceuticals LLC

699 Trade Center Blvd., Suite A

Chesterfield, MO 63005

Attention: [            ]

 

    	6

    	 

    

  

with a courtesy copy to:

 

Flamel Technologies S.A.

33, avenue du Dr. Georges Levy –

Parc Club du Moulin à Vent

69693 Vénissieux Cedex – France

Attention: [           ]

 

For the Secured Party:

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Attention: Structured Products

 

with a courtesy copy to:

 

Katten Muchin Rosenman LLP

575 Madison Avenue

New York, New York 10022-2585

Attention: Mark I. Fisher

Facsimile: (212) 894-5877

 

11.         
General. 

 

(a)          This
Agreement shall be binding upon the assigns or successors of Eclat and shall inure to the benefit of and be enforceable by Secured
Party and its successors and assigns.

 

(b)          This
Agreement contains the entire understanding of the Parties with respect to the matters covered hereby and supersedes any and all
other written and oral communications, negotiations, commitments and writings with respect hereto. The provisions of this Agreement
may be waived, modified, supplemented or amended only by an instrument in writing signed by each Party.

 

(c)          If
any provision contained in this Agreement shall be invalid, illegal or unenforceable in any respect under any law, the validity,
legality and enforceability of the remaining provisions shall not be affected or impaired thereby. The Parties shall endeavor in
good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of
which comes as close as possible to that of the invalid, illegal or unenforceable provision.

 

    	7

    	 

    

  

(d)          This
Agreement and any document, certificate or statement delivered pursuant thereto or in connection herewith shall be considered to
have been relied upon by the Parties and shall survive the execution and delivery of this Agreement regardless of any investigation
made by any Party, and shall continue in force until the Obligations shall have been fully paid and performed, and Secured Party
shall not be deemed to have waived, any default that may arise by reason of any representation or warranty proving to have been
false or misleading, notwithstanding that the Secured Party may have had notice or knowledge that such representation or warranty
was false or misleading on the date hereof.

 

(e)          Neither
the failure of, nor any delay on the part of, any Party in exercising any right, power or privilege hereunder, or under any agreement,
document or instrument mentioned herein, shall operate as a waiver thereof, nor shall any single or partial exercise of any right,
power or privilege hereunder, or under any agreement, document or instrument mentioned herein, preclude other or further exercise
thereof or the exercise of any other right, power or privilege; nor shall any waiver of any right, power, privilege or default
hereunder, or under any agreement, document or instrument mentioned herein, constitute a waiver of any other right, power, privilege
or default or constitute a waiver of any default of the same or of any other term or provision. No course of dealing and no delay
in exercising, or omission to exercise, any right, power or remedy accruing to the Secured Party upon any default under this Agreement,
or any other agreement shall impair any such right, power or remedy or be construed to be a waiver thereof or an acquiescence therein;
nor shall the action of the Secured Party in respect of any such default, or any acquiescence by it therein, affect or impair any
right, power or remedy of the Secured Party in respect of any other default. All rights and remedies herein provided are cumulative
and not exclusive of any rights or remedies otherwise provided by law.

 

12.         Release
of Collateral. 

 

The Secured Party shall
promptly upon the request of Eclat (a) release any lien on any Collateral granted to the Secured Party under this Agreement
upon the payment and performance in full of all Obligations, and at Eclat’s expense, promptly (x) deliver to Eclat any Collateral
in the Secured Party’s possession following the release of such Collateral and (y) execute and deliver to Eclat such documents
as Eclat may reasonably request to evidence such release.

 

 

[Signature Page Follows]

 

    	8

    	 

    

 

IN WITNESS WHEREOF,
each of the Parties hereto has caused this Agreement to be executed and delivered by its duly authorized officer on the date first
set forth above.

 

	ECLAT PHARMACEUTICALS LLC	 
	 	 
	By:  	     /s/ Michael S. Anderson	 
	Name:  Michael S. Anderson	 
	Title:   CEO	 
	 	 
	DEERFIELD PRIVATE DESIGN FUND II, L.P.	 
	By: Deerfield Mgmt L.P., its General Partner	 
	By: J.E. Flynn Capital, LLC, its General Partner	 
	 	 
	By: 	     /s/ James E. Flynn	 
	Name:  James E. Flynn	 
	Title:    President	 
	 	 
	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.	 
	By: Deerfield Mgmt L.P., its General Partner	 
	By: J.E. Flynn Capital, LLC, its General Partner	 
	 	 
	By:  	     /s/ James E. Flynn	 
	Name:  James E. Flynn	 
	Title:    President	 

 

    	9

    	 

    

 

SCHEDULE 4(c)

TO

SECURITY AGREEMENT

 

CHIEF EXECUTIVE AND MAILING OFFICE

LOCATION OF COLLATERAL

 

    	10INVESTMENT MANAGEMENT TRUST AGREEMENT

Amendment No. 1

 

This Amendment made as of March 28, 2013,
amends that certain Investment Management Trust Agreement (the “Agreement”), dated March 24, 2011, by and between Prime
Acquisition Corp. (the “Company”) and American Stock Transfer & Trust Company, LLC, as trustee (the “Trustee”).

 

WHEREAS, the board of directors of the Company
deems it advisable, necessary and has adopted resolutions to: (a) amend paragraph 4 of Article 156 of the Company’s Amended
and Restated Articles of Association (the “Articles”) to permit the continuance of the Company for a period of six
(6) months after the Termination Date (as defined in the Articles) (the “Extension”); and (b) provide its stockholders
with the opportunity to redeem their Company ordinary shares for cash equal to their pro rata share of the Trust Account in connection
the Extension; and

 

WHEREAS, the Company’s shareholders
have approved the amendment to the Articles to effect the Extension in accordance with the terms of the Articles, and holders of
80% of the IPO Shares have approved this amendment in accordance with the terms of Paragraph 7(c) of the Agreement.

 

IT IS AGREED:

 

1.Defined
Terms.  Defined terms used but not defined in this Amendment are as defined in the Agreement.

 

2.Amendments.  The
parties amend the Agreement as follows:

 

(a)The
first sentence of Paragraph 1(i) is amended to read in its entirety as follows:

 

“Commence liquidation of the
Trust Account only after receipt of and only in accordance with the terms of a letter (“Termination Letter”),
in a form substantially similar to that attached hereto as either Exhibit B, Exhibit C, or Exhibit D signed
on behalf of the Company by its Chief Executive Officer or Chief Financial Officer, and complete the liquidation, in whole or in
part, of the Trust Account and disburse the Property in the Trust Account (which disbursement shall include, in the event of a
Business Combination (as hereafter defined), payment of the Deferred Compensation to the Representative) only as directed in the
Termination Letter and the other documents referred to therein.”

 

(b)A
new exhibit referred to as “Exhibit D” is added in the form attached hereto.

 

3.Miscellaneous.

 

(a)This
Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving
effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.  It
may be executed in several counterparts, each one of which shall constitute an original, and together shall constitute but one
instrument.

 

(b)As
to any claim, cross-claim or counterclaim in any way relating to this Amendment, each party waives the right to trial by jury.

 

    	 

    	 

    

 

(c)The
parties hereto consent to the jurisdiction and venue of any state or federal court located in the City of New York, Borough of
Manhattan, for purposes of resolving any disputes hereunder.

 

(d)Each
of the Trustee and the Company hereby represents that it has the full right and power and has been duly authorized to enter into
this Amendment and to perform its respective obligations as contemplated hereunder.

 

[Signature page follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties have duly
executed this Amendment No. 1 to the Investment Management Trust Agreement as of the date first written above.

	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Trustee
	 
	By:	
        /s/ Michael A. Nespoli

	Name:  	Michael A. Nespoli
	Title:	Senior Vice President
	 
	PRIME ACQUISITION CORP.
	 
	By:	
        /s/ Diana Liu

	Name:	Diana Liu
	Title:	Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment Management

Trust Agreement

(Amendment No. 1)

    	 

    	 

    

 

EXHIBIT D

 

[Letterhead of Company]

 

[Insert date]

 

American Stock Transfer

& Trust Company, LLC

59 Maiden Lane

New York, New York 10038

Attn:

 

Re:Trust Account No. [                    ]
Partial Termination Letter

 

Gentlemen:

 

Pursuant to Section 1(j) of the Investment
Management Trust Agreement between Prime Acquisition Corp. (“Company”) and American Stock Transfer & Trust Company,
LLC (“Trustee”), dated as of March 24, 2011 (“Trust Agreement”), this is to advise you that the Company
has completed the amendment of its Amended and Restated Memorandum and Articles of Association to provide for a continuance of
the Company for a period of six (6) months after the Termination Date (as defined in the Articles) (the “Extension”)
and that in connection with the Extension the Company has granted redemption rights to holders of an aggregate of _____________
IPO Shares. Attached hereto is a copy of the minutes of the meeting of the Board of Directors of the Company and of the Shareholders
of the Company relating thereto, certified by an executive officer of the Company as true and correct and in full force and effect.  Capitalized
terms used herein and not otherwise defined shall have the meanings ascribed to them in the Trust Agreement.

 

In accordance with the terms of the Trust
Agreement, we hereby authorize you to commence liquidation of a portion of the Trust Account in the amount of $_________________
to the effect that such of funds will be available for transfer to the account or accounts that the Company shall direct on _____________,
2013. You are hereby directed and authorized to transfer the funds so liquidated from the Trust Account to Public Shareholders
who exercised their conversion rights in connection with the Extension, in an amount equal to their pro rata share of the amounts
in the Trust Account as of two business days prior to the commencement of the Company’s tender offer relating to the Extension
(including the Deferred Compensation and any income actually received on the Trust Account balance and held in the Trust Account,
but less an amount equal to estimated taxes that are or will be due on such income at an assumed rate of [___]). The balance of
the funds shall remain in the Trust Account and continue to be held in accordance with the terms of the Trust Agreement.

 

 

	Very truly yours,
	 
	PRIME ACQUISITION CORP.
	 
	By:	 
	Name:	
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]